Study identifier:D4920C00002
ClinicalTrials.gov identifier:NCT04610892
EudraCT identifier:2020-000840-75
CTIS identifier:N/A
A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction and Persistent Inflammation
Coronary Heart Disease (CHD)
Phase 2
No
-
All
423
Interventional
21 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Nov 2023 by AstraZeneca
AstraZeneca
Thrombolysis in Myocardial Infarction (TIMI) Study Group
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: MEDI6570 Low dose Monthly Subcutaneous administration. | Biological/Vaccine: MEDI6570 MEDI6570 Other Name: None |
Experimental: MEDI6570 Medium dose Monthly Subcutaneous administration. | Biological/Vaccine: MEDI6570 MEDI6570 Other Name: None |
Experimental: MEDI6570 High dose Monthly Subcutaneous administration. | Biological/Vaccine: MEDI6570 MEDI6570 Other Name: None |
Placebo Comparator: Placebo Low dose Monthly Subcutaneous administration. | Biological/Vaccine: Placebo Buffer Other Name: None |
Placebo Comparator: Placebo Medium dose Monthly Subcutaneous administration | Biological/Vaccine: Placebo Buffer Other Name: None |
Placebo Comparator: Placebo High dose Monthly Subcutaneous administration | Biological/Vaccine: Placebo Buffer Other Name: None |